Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field

Dyslipidemia is one of the most common disorders worldwide, which, if left untreated, results in a multitude of complications. Thus proper diagnostics, which includes identifying of secondary causes of dyslipidemia is crucial. Endocrine disorders are an important cause of secondary dyslipidemia. Thi...

Full description

Bibliographic Details
Main Authors: Michal Olejarz, Ewelina Szczepanek-Parulska, Marek Ruchala
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2024.1354098/full
_version_ 1827299175892516864
author Michal Olejarz
Ewelina Szczepanek-Parulska
Marek Ruchala
author_facet Michal Olejarz
Ewelina Szczepanek-Parulska
Marek Ruchala
author_sort Michal Olejarz
collection DOAJ
description Dyslipidemia is one of the most common disorders worldwide, which, if left untreated, results in a multitude of complications. Thus proper diagnostics, which includes identifying of secondary causes of dyslipidemia is crucial. Endocrine disorders are an important cause of secondary dyslipidemia. This paper aims to review the publications on lipoprotein alterations in endocrine disorders from the past two years and provide an overview of the recent discoveries in this dynamically developing and large field. Significant changes in lipoprotein serum concentrations are present in most endocrinological diseases and can be modified with proper treatment. Some lipoproteins have also been proposed as markers in some endocrine diseases, e.g., thyroid carcinoma. From the scope of endocrine disorders, the largest number of studies explored the lipoprotein changes in polycystic ovary syndrome and in women during the menopausal and peri-menopausal period. Even though the association of thyroid disorders with dyslipidemia is already well studied, new research has delivered some exciting findings about lipoprotein alterations in euthyroid patients with either positive antithyroid peroxidase antibodies or reduced sensitivity to thyroid hormones. The problem of the adverse metabolic profile, including dyslipidemia in hypoprolactinemia has been recognized. Moreover, this review describes other significant discoveries encompassing lipoprotein alterations in disorders of the adrenals, thyroid, parathyroid glands, pituitary, and gonads. The up-to-date knowledge of the influence of endocrine disorders and hormonal changes on serum lipoproteins is prudent as it can significantly impact therapeutic decisions.
first_indexed 2024-04-24T15:29:33Z
format Article
id doaj.art-18d5df1a457b47f1a2d4a44ccd6a63a9
institution Directory Open Access Journal
issn 1664-2392
language English
last_indexed 2024-04-24T15:29:33Z
publishDate 2024-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj.art-18d5df1a457b47f1a2d4a44ccd6a63a92024-04-02T04:48:58ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922024-04-011510.3389/fendo.2024.13540981354098Lipoprotein alterations in endocrine disorders - a review of the recent developments in the fieldMichal OlejarzEwelina Szczepanek-ParulskaMarek RuchalaDyslipidemia is one of the most common disorders worldwide, which, if left untreated, results in a multitude of complications. Thus proper diagnostics, which includes identifying of secondary causes of dyslipidemia is crucial. Endocrine disorders are an important cause of secondary dyslipidemia. This paper aims to review the publications on lipoprotein alterations in endocrine disorders from the past two years and provide an overview of the recent discoveries in this dynamically developing and large field. Significant changes in lipoprotein serum concentrations are present in most endocrinological diseases and can be modified with proper treatment. Some lipoproteins have also been proposed as markers in some endocrine diseases, e.g., thyroid carcinoma. From the scope of endocrine disorders, the largest number of studies explored the lipoprotein changes in polycystic ovary syndrome and in women during the menopausal and peri-menopausal period. Even though the association of thyroid disorders with dyslipidemia is already well studied, new research has delivered some exciting findings about lipoprotein alterations in euthyroid patients with either positive antithyroid peroxidase antibodies or reduced sensitivity to thyroid hormones. The problem of the adverse metabolic profile, including dyslipidemia in hypoprolactinemia has been recognized. Moreover, this review describes other significant discoveries encompassing lipoprotein alterations in disorders of the adrenals, thyroid, parathyroid glands, pituitary, and gonads. The up-to-date knowledge of the influence of endocrine disorders and hormonal changes on serum lipoproteins is prudent as it can significantly impact therapeutic decisions.https://www.frontiersin.org/articles/10.3389/fendo.2024.1354098/fullendocrine disorderslipoproteinsHDL-cholesterolLDL-cholesteroltriglycerideslipoprotein (a)
spellingShingle Michal Olejarz
Ewelina Szczepanek-Parulska
Marek Ruchala
Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field
Frontiers in Endocrinology
endocrine disorders
lipoproteins
HDL-cholesterol
LDL-cholesterol
triglycerides
lipoprotein (a)
title Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field
title_full Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field
title_fullStr Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field
title_full_unstemmed Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field
title_short Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field
title_sort lipoprotein alterations in endocrine disorders a review of the recent developments in the field
topic endocrine disorders
lipoproteins
HDL-cholesterol
LDL-cholesterol
triglycerides
lipoprotein (a)
url https://www.frontiersin.org/articles/10.3389/fendo.2024.1354098/full
work_keys_str_mv AT michalolejarz lipoproteinalterationsinendocrinedisordersareviewoftherecentdevelopmentsinthefield
AT ewelinaszczepanekparulska lipoproteinalterationsinendocrinedisordersareviewoftherecentdevelopmentsinthefield
AT marekruchala lipoproteinalterationsinendocrinedisordersareviewoftherecentdevelopmentsinthefield